Influenza is a highly infectious airborne disease with an important epidemiological and societal burden; annual epidemics and pandemics have occurred since ancient times, causing tens of millions of deaths. A hundred years after this virus was first isolated, influenza vaccines now ensure effective protection, and the preparations used display good safety and tolerability profiles.
Innovative tools, such as recombinant technologies and intra-dermal devices, are currently being investigated in order to elicit good immunity even in the event of unforeseen changes in the virus due to drift and antigenic shift or the co-circulation of different viral strains.
The recurring mutations of influenza strains has prompted the recent introduction of a quadrivalent inactivated vaccine. In the near future, scientific research will strive to produce a long-lasting universal vaccine containing an antigen that is not subject to genetic modifications, and surveillance systems will be implemented in order to exactly predict circulating strains.
Gasparini R, Amicizia D, Lai PL, et al. Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part I: Influenza life-cycle and currently available drugs. J Prev Med Hyg. 2014;55(3):69-85.
Gasparini R, Amicizia D, Lai PL, et al. Compounds with anti-influenza activity: present and future of strategies for the optimal treatment and management of influenza. Part II: Future compounds against influenza virus. J Prev Med Hyg 2014;55:109-29.
Hause BM, Collin EA, Liu R, et al. Characterization of a novel influenza virus in cattle and Swine: proposal for a new genus in the Orthomyxoviridae family. MBio 2014;5:e00031-14.
Collin EA, Sheng Z, Lang Y, et al. Cocirculation of two distinct genetic and antigenic lineages of proposed influenza D virus in cattle. J Virol 2015;89:1036-42.
Ducatez MF, Pelletier C, Meyer G. Influenza D virus in cattle, France, 2011-2014. Emerg Infect Dis 2015;21:368-71.
Soema PC, Kompier R, Amorij JP, et al. Current and next generation influenza vaccines: Formulation and production strategies. Eur J Pharm Biopharm. 2015;94:251-63.
Pappas G, Kiriaze IJ, Falagas ME. Insights into infectious disease in the era of Hippocrates. Int J Infect Dis 2008 ;12:347-50.
Kohn GC Encyclopedia of Plague and Pestilence: From Ancient Times to the Present. Infobase Publishing, 2007.
Beveridge WIB. Influenza: The Last Great Plague. London: Heineman Educational Books, 1977.
Wood JM, Influenza. In (Crovari P, Principi N: Eds): Le vaccinazioni. Pacini Editore, Pisa, 2000.
Kuszewski K., Brydak. L. The epidemiology and history of influenza. Biomed Pharmacoter 2000;54:188-95.
Gintrac H. Grippe. In nouveau dictionnaire de mèdicine et de chirurgie pratiques, directeur de la redaction: le docteur Jaccoud. 1872, Tome 16, page. 728-753.
de Souza CM. The Spanish flu epidemic: a challenge to Bahian medicine. Hist Cienc Saude Manguinhos 2008;15:945-72.
Potter CW. A history of influenza. J Appl Microbiol 2001;91:572-9.
Waring J.I. A History of Medicine in South Carolina 1900-70. South Carolina Medical Association, 1971.
Bazin H. Vaccination: a history. Editions John Libbey Eurotext. Montrouge. France, 2011.
Renaud F, Hansen W, Freney J. Dictionnaire des precurseurs en bacteriologie, SFM éditions Eska, 2005, 249 pages.
Craddock S, Giles-Vernick T, Gunn JL. Influenza and Public Health: Learning from Past Pandemics. Earthscan, 2010 - 293 pages.
Smith W, Andrewes CH, Laidlaw PP. A virus obtained from influenza patients. Lancet 1933;2:66-8.
Smith W, Andrewes CH, Stuart Harris CH. The immunization of human volunteers. Special Rep Ser Med Res Council 1938;228:137-44.
Francis T Jr. Vaccination against inﬂuenza. Bull. World Health Organ 1953;8:725–741.
Burnett FM. Influenza virus infection of the chick embryo lung. Br J Exp Pathol 1940;21:147-53.
Stanley WM. The preparation and properties of influenza virus vaccines concentrated and purified by differential centrifugation. J Exp Med 1945;81:193-218.
Parodi V, de Florentiis D, Martini M, et al. Inactivated influenza vaccines: recent progress and implications for the elderly. Drugs Aging 2011;28:93-106.
Barberis I, Martini M, Iavarone F, et al. Available influenza vaccines: immunization strategies, history and new tools for fighting the disease. J Prev Med Hyg 2016;57:E41-6.
Weir JP, Gruberb MF. An overview of the regulation of inﬂuenza vaccines in the United States. Influenza other respir viruses 2016;10:354-60.
Parkman PD, Hopps HE , Rastogi SC, et al. Summary of clinical trials of influenza virus vaccines for adults. J Infect Dis 1977;136:722-30.
Hampson AW. Vaccines for pandemic influenza. The history of our current vaccines, their limitations and the requirements to deal with a pandemic threat. Ann Acad Med Singapore 2008;37:510-7.
Crovari P, Alberti M, Alicino C. History and evolution of influenza vaccines. J Prev Med Hyg 2011;52:91-94.
Gianchecchi E, Trombetta C, Piccirella S, et al. Evaluating influenza vaccines: progress and perspectives. Future Virology 2016;11:379-393 .
Kendal AP, Maassab HF, Alexandrova GI, et al. Development of cold-adapted recombinant live attenuated influenza vaccines in the U.S.A. and U.S.S.R. Antiviral Res 1982;1:339-365.
Zaman M, Ashraf S, Dreyer NA, Toovey S. Human infection with avian inﬂuenza virus, Pakistan, 2007. Emerg Infect Dis 2011;17:1056–1059.
Food and Drug Administration (FDA). FluMist. Prior Approval Supplemental BLA. April 2007. Available at: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4292B1-02.pdf. Last access: 25th July 2016.
Dawood FS, Iuliano AD, Reed C et al. Estimated global mortality associated with the ﬁrst 12 months of 2009 pandemic inﬂuenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012;12:687–695.
Falsey AR, Treanor JJ, Tornieporth N, et al. Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose inﬂuenza vaccine in adults 65 years of age and older. J Infect Dis 2009;200:172–180.
Durando P, Iudici R, Alicino C, et al. Adjuvants and alternative routes of administration towards the development of the ideal inﬂuenza vaccine. Hum Vaccin 2011;7(Suppl):29–40.
Holland D, Booy R, De Looze F et al. Intradermal inﬂuenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial. J Infect Dis 2008;198:650–658.
Arnou R, Icardi G, De Decker M et al. Intradermal inﬂuenza vaccine for older adults: a randomized controlled multicenter phase III study. Vaccine 2009;27:7304-7312.
Belshe RB, Newman FK, Cannon J, et al. 2004. Serum antibody responses after intradermal vaccination against inﬂuenza. N Engl J Med 2004;351:2286–2294.
Bragazzi NL, Orsi A, Ansaldi F, et al. Fluzone® Intra-dermal (Intanza® / Istivac® Intra-dermal): an updated overview. Hum Vaccin Immunother 2016, in press.
Tisa V, Barberis I, Faccio V et al. Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden. J Prev Med Hyg 2016;57:E28-33.
Treanor JJ, El Sahly H, King J, et al. Protective efﬁcacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok) against inﬂuenza in healthy adults: a randomized, placebo-controlled trial. Vaccine 2011;29:7733–7739.
Baxter R, Patriarca PA, Ensor K et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin inﬂuenza vaccine administered intramuscularly to healthy adults 50-64 years of age. Vaccine 2011;29:2272–2278.
Sridhar S. Heterosubtypic T-Cell Immunity to Influenza in Humans: Challenges for Universal T-Cell Influenza Vaccines. Front Immunol 2016;7:195.
Wiersma LC, Rimmelzwaan GF, de Vries RD. Developing Universal Influenza Vaccines: Hitting the Nail, Not Just on the Head. Vaccines (Basel) 2015;3:239-62.